Across TCGA pan-cancer cohorts, NANOS1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NANOS1 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher NANOS1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NANOS1 expression acts as an unfavorable survival marker.

ACC and DLBC are the cancer types where NANOS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: NANOS1 tumor-vs-normal RNA expression · all NANOS1 data types